Recruiting
Phase 3

IBI363 vs. Docetaxel

Sponsor:

Fortvita Biologics (USA)Inc.

Code:

NCT07217301

Conditions

iO Resistant sqNSCLC

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

IBI363

Control Arm

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-31. This information was provided to ClinicalTrials.gov by Fortvita Biologics (USA)Inc. on 2026-03-09.